Uncover the plum stoics behind the purchase of ibin creatures.

After waiting for most of the year, Plum Bio, after getting permission from the Ministry of Commerce, suddenly announced the proposed termination of the acquisition of Ipin Bio, so that the position of the industry giant already ready to take place is changing againHRRNew Financial Correspondent Sun Ruili HRRvariable HRR" the negotiations are continuing and it is not yet clear whether the acquisition will be terminated"Following the announcement of the suspension of the suspension of the acquisition of Ningxia Yipin Biotech Co., Ltd("Ipin Bio"), the relevant person in charge of Meihua Biotech Group Co., Ltd("Plum Biology") told New Financial WatchHRRAugust 12, Meihua Bio first issued a public announcement to terminate the acquisition of Ipin Bio, "due to the restructuring of the proposed acquisition of assets have occurred affecting the transaction subject matter seamount to meet the restructuring conditions, the company comprehensively consider the various risk factors of this acquisition, to decide to terminate the issue of shares and cash to purchase assets and support inglisance fund raising matters."HRRissued at the same time as the announcement, there is another long-awaited news for both the acquirer and investors, Plum Bio received the Ministry of Commerce's Antimonopoly Bureau issued a "review decision notice", the acquisition of 100% equity in TheuTHE HRR
" TWO MESSAGES PUT TOGETHER, A LITTLE TOO UNEXPECTEDPlum Bio One investor saidHRRthe outside world's impression of plum creatures may have been largely derived from the plum MSG, or sodium glutamate, placed on supermarket shelves, which is also the largest source of revenue for plum organismsIn its 2015 half-yearly report, MSG achieved revenue of RMB 2.539 billion, accounting for more than 40% of its operating incomeIn addition, the main products of plum biology for other amino acid products, fertilizers, proteins and so on Its main customers include many well-known food enterprises, such as Mrs Le, Hodge, Bridge, Chengdu Guotai, Master Kang, Unification, today's Mai Lang, Hualong, Unilever, Nestle and so on HRR a year ago, as one of the leading companies in the amino acid industry, Plum Bio decided to acquire Epin Bio, which also has a certain position in the industry On November 14 of that year, Meihua Bio issued an asset acquisition plan, proposed to Ipin Group, Honghui Investment and other non-public issue of shares and pay cash to buy its holding of 100% of Ipin Bio, the subject price of the transaction is 3.822 billion yuan, to raise supporting funds not more than 1.041 billion yuan HRR the background is that the entire amino acid industry is struggling to survive a two-year period of overcapacity, the industry is facing a price war, the market is very depressed HRR industry insiders told the New Financial Observer reporter, two or three years ago, the industry's largest MSG production enterprises with stop production, relocation and other tricks to deal with overcapacity Another well-known MSG manufacturer simply shut down a large part of the production line on the grounds of equipment replacement IN CONTRAST TO THE ABOVE-MENTIONED PEERS, THE HRR
, MEIHUA MSG WANTS TO TAKE ADVANTAGE OF THE OPPORTUNITY TO SEIZE MARKET SHARE A recent research report from Qilu Securities said that Meihua MSG has a production capacity of 600,000 tons of MSG, 360,000 tons of lysine, susine 150,000 tons, respectively, ranked second, second and first in the domestic industry, the market share of 25%, 18%, 40%, respectively Such as the success of the acquisition of Ippin biological, plum MSG production capacity will reach 830,000 tons, lysine fold pure 600,000 tons, Susine 210,000 tons, respectively, ranked second, second and first in the domestic industry, the production capacity market share increased to 35%, 30%, 55% HRR Plum Bio said in a statement: "The acquisition of Ipin Bio as an opportunity to achieve a second leap." Upon completion of the acquisition, the two sides will collaborate in research and development, technology, channels, management and automation, which will enhance the company's overall competitive ness in the field of MSG and amino acids "HRR " their logic was originally this, after the acquisition of Ipin, lysine, Susine industry left two giants, can join forces to monopolize An industry insider commented HRR however, the first surprise in the acquisition process suddenly occurred On January 27, 2015, Meihua Bio suddenly learned that The Equity of Ipin Bio was frozen by the Chengdu Intermediate People's Court Affected by the incident, Meihua Bio said in a subsequent announcement that the restructuring of The Chinese Securities Regulatory Commission (Weibo) will not be declared to the China Securities Regulatory Commission until the situation of the judicial freeze on Ipin Bio's shares has not been eliminated HRR fortunately, the court lifted the freeze on the 44.1849% stake in Ipin Bio HRR wave after wave, in March this year, Ipin Bio due to patent infringement by south Korean peer giant Shijie (CJ) First Sugar Co., Ltd (hereinafter referred to as "Hijie") to court HRR , like the equity freeze, said it was still "after-knowing." Through the form of an official letter, Plum Bio to Ipin biological verification, the response is that no legal procedures received by the judiciary, in addition to the incident will not affect the company's production and operation and mergers and acquisitions between the two sides HRR , however, and soon the court case was filed, and plaintiff Sijger asked Epin Biology to stop producing, selling and destroying its patented products, L-Lysine sulfates, L-Lysine hydrochloride, and so on After HRR , Plum Bio received a notice from the Ministry of Commerce to extend the deadline for further review of the acquisition of 100% equity in Ipn Bio by Plum Bio HRR there is an early gap hrR which seems to have some "ideas" about two incidents that have had a negative impact on the acquirer in the course of the takeover negotiations HRR two incidents, and Plum Bio said it was informed by the outside world, which was then verified to Ipin Bio, and immediately issued a notice to explain the situation HRR in the case of patent infringement in Ipin bio, plum biology is in the form of an official letter of formal inquiry (to learn the patent infringement news, plum biology to Ipin biological issued "inquiry letter"), and the other side of the main content of the reply to the publication In the reply, Ipsin first said that it had not received the relevant notice through formal channels, and then believed that the incident would not affect the parties HRR , however, the court quickly filed a case, and the publicity seemed to make the plum creature feel unoptimistic HRR " Ipin is suspected of infringing Higer's patent, if Ipin and Hijdge lost the case, then it will be hit hard, plum at this time to buy Ipin is a great risk Industry insiders say HRR in addition, he also believes that The Products of Ipsin Bio, which Higgs points out patent infringement, are exactly what Plum Creatures do not have "What ispering is owned by plum creatures And plum biology does not have those technology, Ipin biological has been revealed suspected of infringing the patent of Hijie lawsuit "HRR finally on August 12, Plum Bio announced the intention to terminate the acquisition of Ipin Bio HRR Plum Biology has relevant people said that The patent infringement of Ipin Bio is the cause of the acquisition was called off HRR " is not a single thing, and there are many factors that influence this acquisition On August 21st, the person in charge of meihua biology told The New Financial Observer HRR before, there are brokerage research reports show that this year, MSG prices rose 1000 yuan / ton, there will be room for growth in the future Qilu securities analysis that the next two years of new capacity is difficult to put, and MSG price simply under 11000 yuan / ton of obsolete production capacity is difficult to restart (small factory processing costs than MSG leading enterprises more expensive 2000 yuan / ton, taking into account the recruitment of personnel, equipment restart costs, MSG market price to 11000 yuan / ton to consider production), demand to maintain 6% growth, the industry's supply tension further highlighted Domestic leading enterprises have strong pricing capacity, MSG industry is expected to enter the price increase cycle HRR In view of the improving market, some industry analysts believe that Meihua MSG has no need to acquire Ipon Bio, expand their market share HRR , from the financial data of Ipin bio-data, its corresponding net profit for the 2013 and January-July 2014 periods was -0.12 billion yuan and -0.82 billion yuan, respectively, and net profit declined HRR earlier, The relevant person in charge of Ipin Biology had directly stated that the company was short of money In this acquisition, Ipin Bio has pledged net profit of not less than 272 million yuan, 301 million yuan and 335 million yuan for 2015 to 2017 If the Company fails to meet the stated performance of the aforementioned commitments, it will be compensated in cash by The Ispin Group, and the Chairman of the Group, Zhai Xiaoping, shall bear joint and several liability HRR even with this commitment, the risk of acquiring Ipin Bio at this time is clearly high HRR on the further action of Plum Bio on the acquisition, the person in charge stressed: "The two sides are still in negotiations." "HRR " Now both sides have some ideas, and future acquisitions are fraught with uncertainty She said HRR August 19, after the August 12 issue of the suspension notice, and then issued a suspension notice, still said that "there is a greater uncertainty about this reorganization."HRR for the current form, the above-mentioned plum biology related to the relevant person-in-charge to the new financial observation reporter, next Thursday, the company re-licensing, on the acquisition if there are new trends will be announced HRR Multi-Investment HRR many people in the industry believe that the Ipin creatures affected by many negative events are no longer the original Ipin creatures In fact, today's plum creatures are no longer the original plum creatures HRR 2014, during the downturn, Plum Bio not only made the acquisition of Ipone Bio In May 2014, Meihua Bio completed the acquisition of 50.1% of Shanxi Guangsheng Pharmaceutical Packaging Co., Ltd ("Guangsheng Pharmaceuticals") through equity transfer and capital increase Guangsheng Pharmaceutical is a leading domestic hollow capsule production enterprise, in 2014 to achieve 84.39 million yuan of operating income HRR in June 2014, Meihua Bio acquired a 100% stake in Dalian Hanxin Biopharmaceutical Co., Ltd ("Hanxin Bio)" for 600 million yuan The company's main products are vaccines, including the recombinant hepatitis B vaccine (Hanson yeast) and the human rabies vaccine (ground mouse kidney cells) In 2014, it achieved revenue of 38.26 million yuan HRR 's acquisition of the two biopharmaceutical companies is the first foray into the pharmaceutical sector, with the two companies achieving revenues of 123 million yuan in 2014 and 180 million yuan in the first half of 2015 HRR " now plum biology has amino acids, fertilizer, medicine and other industries, at present, amino acids are relatively stable, fertilizer sector gross margin is still declining, profit loss, only medicine to maintain a high growth "The industry said HRR Plum Bio has said that the company in the main amino acid industry, at the same time, to the biopharmaceutical field into the test water In the future, we will integrate products and businesses in the pharmaceutical sector, and on the basis of the existing introduction of outstanding teams in the industry to build the pharmaceutical business segment of listed companies HRR 3 years ago, Plum Bio also established the Prolando sugar (used in medicine, health care products, capsules and other fields) production base and production line Last year it acquired Guangsheng Pharmaceuticals, which is the representative company that produces capsules It is understood that the current plum biology in The Plum Poly sugar on the income is considerable, annual profit of about 100 million yuan HRR it's worth noting that both of these pharmaceutical mergers and acquisitions have now changed The person in charge of Meihua biology told the new financial observer reporter that Guangsheng Pharmaceutical is planning a new three-board listing HRR , which it acquired in June last year for $600 million, sold a 51% stake in Liaoning Amy Biovaccine Technology Group Co., Ltd for $337 million in July At that time, Hanxin Bio was priced at 660 million yuan, compared with the acquisition, a value-added of 60 million yuan HRR this move is considered by the industry to complement the cash flow of plum bio HRR investment in the pharmaceutical industry has indeed brought a lot of benefits to Meihua biological, but there are also industry experts said that the pharmaceutical sector investment needs professional, focused, we must pay attention to research and understanding of the industry, while investing in the pharmaceutical industry risk is also relatively large HRR "We have a merger and acquisition fund and will grow in a variety of areas in the future." The person in charge of plum biology told The New Financial Observer HRR is understood that the above-mentioned merger and acquisition fund was established in May this year, Meihua Bio invested 100 million yuan, and Oriental Securities (18.16, -1.74, -8.74%) of the merger and acquisition fund platform Oriental Reed Equity Fund and other partners signed a partnership agreement to jointly set up the East China Dollar Merger and Acquisition Investment Fund (limited partnership) The partnership prioritizes the company's industrial integration, through mergers and acquisitions and restructuring of target companies with good growth potential and strategic value in the company's business, with major investment areas covering food, condiments, pharmaceuticals and health care products HRR waited for most of the year, plum bio after getting permission from the Ministry of Commerce, suddenly with a proposed termination of the acquisition of Ipin Bio announcement, so that the already ready to take place in the position of the industry giant once again changed HRR New Financial Correspondent Sun Ruili HRR variable HRR " the negotiations are continuing and it is not yet clear whether the acquisition will be terminated "Following the announcement of the suspension of the suspension of the acquisition of Ningxia Yipin Biotech Co., Ltd ("Ipin Bio"), the relevant person in charge of Meihua Biotech Group Co., Ltd ("Plum Biology") told New Financial Watch HRR August 12, Meihua Bio first issued a public announcement to terminate the acquisition of Ipin Bio, "due to the restructuring of the proposed acquisition of assets have occurred affecting the transaction subject matter seamount to meet the restructuring conditions, the company comprehensively consider the various risk factors of this acquisition, to decide to terminate the issue of shares and cash to purchase assets and support inglisance fund raising matters."HRR issued at the same time as the announcement, there is another long-awaited news for both the acquirer and investors, Plum Bio received the Ministry of Commerce's Antimonopoly Bureau issued a "review decision notice", the acquisition of 100% equity in Theu THE HRR
" TWO MESSAGES PUT TOGETHER, A LITTLE TOO UNEXPECTED Plum Bio One investor said HRR the outside world may have much of the impression of plum biology, which is also plum sesame, which is placed on supermarket shelves.